Medical device innovation: Prospera
Natera
Natera’s Prospera is a transplant rejection assessment blood test that can evaluate the rejection of a transplanted kidney.
The cell-free DNA technology has a 95% negative predictive value and misses three times fewer rejections than gold-standard serum creatinine. Prospera provides early warning signs of a transplant rejection to reduce the likelihood of renal allograft failure with a single noninvasive blood draw.
Natura also makes a Prospera transplant rejection assessment for hearts and lungs.
Next >>